1778 Participants NeededMy employer runs this trial

Zenagamtide for Type 2 Diabetes

(AMBITION 7 Trial)

Recruiting at 329 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Novo Nordisk A/S
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

Are You a Good Fit for This Trial?

This trial is for adults with type 2 diabetes who are already taking 1 to 3 diabetes medications and have a higher risk of heart or blood vessel problems. Participants should not have other major health issues that would prevent safe participation.

What Are the Treatments Tested in This Trial?

Interventions

  • Zenagamtide

Trial Overview

The study compares two injectable treatments: zenagamtide (the new drug) versus insulin glargine, both given once a week. Which treatment each participant gets is decided randomly.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: ZenagamtideExperimental Treatment1 Intervention
Group II: Insulin glargine U-100Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Novo Nordisk A/S

Lead Sponsor

Trials
1,578
Recruited
3,813,000+
Lars Fruergaard Jørgensen profile image

Lars Fruergaard Jørgensen

Novo Nordisk A/S

Chief Executive Officer since 2017

MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark

Martin Holst Lange profile image

Martin Holst Lange

Novo Nordisk A/S

Chief Medical Officer since 2021

MD from University of Copenhagen